Inhalation Powder Filling via Vacuum Density Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dry powder inhalation formulations face challenges in achieving content uniformity, flowability, and dose consistency, particularly due to variations in particle sizes and ratios of active agents and carriers, which affect the filling process and delivery of a precise dose to the respiratory tract.
Innovation Solution
A filling method utilizing a composition with specific particle size distributions of salmeterol, fluticasone, and lactose, applied under vacuum conditions to achieve ideal bulk and compressed densities, ensuring uniform mixing and efficient filling into blisters or capsules, thereby ensuring consistent and accurate delivery of fine particle doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If particle sizes of active agents and carriers are varied to improve content uniformity and flowability, then manufacturing precision and reliability improve, but device complexity increases due to need for precise particle size control
Solution Approach 1:
The patent applies parameter changes by optimizing the particle size distribution of lactose carrier (d50: 40-80 μm) and active agents (d50: 1-3 μm), and controlling the bulk density (0.40-0.60 g/mL) and compressed density (0.70-0.90 g/mL) ratios to achieve content uniformity and flowability without excessive device complexity
Solution Approach 2:
The patent uses composite materials by combining fine active agents (salmeterol and fluticasone) with lactose carrier in specific ratios (0.1-5% active agent content), creating a composite powder formulation that achieves both content uniformity and appropriate flow properties
2Reliability
If particle sizes are optimized for respiratory tract delivery, then therapeutic efficacy improves, but filling process difficulty increases
Solution Approach 1:
The patent optimizes particle size parameters where active agents have d50 of 1-3 μm for respiratory delivery while lactose carrier has d50 of 40-80 μm, and controls density parameters (bulk density 0.40-0.60 g/mL, compressed density 0.70-0.90 g/mL) to balance therapeutic efficacy with filling processability
Solution Approach 2:
The patent applies local quality by having different particle size ranges for different components: ultra-fine active agents (1-3 μm) for lung delivery and coarser lactose carrier (40-80 μm) for flowability and filling, allowing each component to optimize its local function
3Productivity
If bulk density and compressed density are optimized for flowability, then productivity improves, but manufacturing precision may be compromised
Solution Approach 1:
The patent optimizes density parameters within specific ranges: bulk density 0.40-0.60 g/mL for flowability and productivity, compressed density 0.70-0.90 g/mL for dose consistency, maintaining both filling rate and dose uniformity through controlled parameter optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures precise and consistent delivery of therapeutic doses by optimizing particle size distributions and densities, enhancing flowability and content uniformity, and preventing agglomeration, thus improving treatment efficacy for respiratory diseases like asthma and chronic obstructive pulmonary disease.
Implementation Method 1
A filling method utilizing a composition with specific particle size distributions of salmeterol, fluticasone, and lactose, applied under vacuum conditions to achieve ideal bulk and compressed densities
Data Source
AI summary
The present invention relates to pharmaceutical powder compositions used by means of inhalation devices. The present invention more particularly relates to a filling method which provides an ideal volume and density for the compositions used in inhalation devices and delivers a desired amount of a fine particle dose to the patient.